Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 11

802P - Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study

Date

21 Oct 2023

Session

Poster session 11

Topics

Tumour Site

Ovarian Cancer

Presenters

Frederik Marmé

Citation

Annals of Oncology (2023) 34 (suppl_2): S507-S542. 10.1016/S0923-7534(23)01937-3

Authors

F. Marmé1, F. Hilpert2, M. Welslau3, J.P. Grabowski4, A. Schneeweiss5, A.D. Hartkopf6, S. Becker7, I. Runnebaum8, D. Bauerschlag9, P. Fasching10, C. Brandi11, J. Rehbein12, R. Glowik13, J. Sehouli14

Author affiliations

  • 1 Gynecologic Oncology Department, UMM - Universitaetsklinikum Mannheim - Medizinische Fakultaet, 68167 - Mannheim/DE
  • 2 Mammazentrum, Krankenhaus Jerusalem, 20357 - Hamburg/DE
  • 3 Hämato-onkologische Schwerpunktpraxis, Klinikum Aschaffenburg, 63739 - Aschaffenburg/DE
  • 4 Department Of Gynecology, Universitätsklinik Charité, Campus Virchow Klinikum, 13353 - Berlin/DE
  • 5 Gynecologic Oncology, Division Gynecologic Oncology, National Center for Tumor Diseases (NCT), University Hospital and German Cancer Research Center, Heidelberg, Germany, 69120 - Heidelberg/DE
  • 6 Center For Women's Healthdepartment, University Hospital of Tuebingen, Tübingen/DE
  • 7 Department Of Obstetrics And Gynecology, Goethe-University Frankfurt am Main - Campus Westend, Frankfurt am Main/DE
  • 8 Gynecology And Reproductive Medicine, Friedrich Schiller-University Jena, Jena/DE
  • 9 Gynecologic Oncology, University Hospital UKSH, 24105 - Kiel/DE
  • 10 Department Of Gynecology And Obstetrics, Universitätsklinikum Erlangen, 91054 - Erlangen/DE
  • 11 Frauenheilkunde / Gynäkology, AGAPLESION Medizinisches Versorgungszentrum Frankfurt gGmbH, Frankfurt / Main/DE
  • 12 Frauenklinik, Städtisches Krankenhaus Kiel GmbH, Kiel/DE
  • 13 Medical Affairs, AstraZeneca GmbH, 22763 - Hamburg/DE
  • 14 Gynecology, Charité - Universitaetsmedizin Berlin, 13353 - Berlin/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 802P

Background

Maintenance treatment with olaparib has demonstrated significant improvements in median progression-free survival (PFS) compared with placebo in patients with platinum-sensitive relapsed ovarian cancer (PSROC) who are in response to platinum-based chemotherapy (PBC). Olaparib was the first-in-class poly (ADP-ribose) polymerase inhibitor (PARPi) approved as monotherapy in the EU in 12/2014 (hard capsules, HC, 400 mg twice daily) in BRCA-mutated (BRCAm) PSROC. In addition, film-coated tablets (FT, 300 mg, twice daily) were approved in 05/2018 in PSROC regardless of BRCA status. After entering routine clinical practice, real-world data on olaparib were limited and this non-interventional study (NIS) was initiated. Here, final survival results are reported.

Methods

The prospective NIS C-PATROL (NCT02503436) was performed at 68 sites (50 hospitals, 18 office-based) in Germany. Routine clinical data were collected of BRCAm PSROC patients treated with olaparib according to label.

Results

Between 28 Oct 2015 and 30 Sep 2019, 282 patients were enrolled. Of these, 269 patients were included in the analysis (median age: 60 yrs; ECOG ≤1: 93%; ≥2 relapses: 32%; ≥3 prior PBC: 34%). 46 patients started with FT and 223 patients with HC; 70 patients switched from HC to FT. Median follow-up was 23.5 months (range 0.00 – 80.5) and median olaparib treatment duration was 13.6 months (0.1–80.9). 10% of patients received olaparib for ≥5 years. Median PFS was 14.3 months (95% CI 12.2–18.0). Median overall survival was 35.4 months (95% CI 29.2–47.1). 132 patients received at least one subsequent medication. Adverse events (AEs) were consistent with known tolerability profile of olaparib. 31 patients (11.3%, safety set: total n=274) discontinued olaparib treatment and 60 patients (21.9%) received reduced olaparib dose due to AEs.

Conclusions

This real-word study supports efficacy and tolerability of olaparib maintenance therapy after PBC in patients with BRCAm PSROC. Long-term exposure to olaparib was observed with no new safety signals.

Clinical trial identification

NCT02503436.

Editorial acknowledgement

Medical writing assistance was provided by Dr. Yvonne Holighaus and Dr. Katharina Bakhaus, Alcedis GmbH, Giessen, funded by AstraZeneca.

Legal entity responsible for the study

AstraZeneca.

Funding

AstraZeneca.

Disclosure

F. Marmé: Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK/Tesaro, Clovis, Pfizer, Lilly; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Novartis, Roche, Gilead/immunomedics, EISAI, PharmaMar, GenomicHealth, Myriad, Seagen; Financial Interests, Institutional, Invited Speaker: Seagen, Daiichi Sankyo, GSK, AstraZeneca; Financial Interests, Institutional, Advisory Board: Roche, Immunicom; Financial Interests, Institutional, Local PI: Roche, Novartis, Eisai, MSD, Vaccibody, GSK; Financial Interests, Institutional, Coordinating PI: AstraZeneca, Roche, Gilead/Immunomedics, German Breast Group, AGO Research GmbH; Financial Interests, Institutional, Funding: AstraZeneca, Lilly, Seagen. F. Hilpert: Financial Interests, Personal, Advisory Board: AstraZeneca, Roche, MSD, PharmaMar; Financial Interests, Personal, Other, Honoraria: AstraZeneca, Roche, MSD, PharmaMar, Pfizer, Novartis. M. Welslau: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Bristol Myers Squibb, Celgene, GILEAD, HEXAL, AMGEN, Janssen, Lilly, Novartis, Roche, Astellas, Sanofi. J.P. Grabowski: Financial Interests, Institutional, Speaker, Consultant, Advisor: AstraZeneca, Tesaro/GSK, Clovis, Roche, Amgen, MSD, Pfizer, Riemser, Eisai. A. Schneeweiss: Financial Interests, Institutional, Research Grant: Celgene, Roche, AbbVie; Financial Interests, Personal, Other, Travel expenses: Celgene, Roche; Financial Interests, Personal, Other, Honoraria: Celgene, Pfizer, AstraZeneca, Novartis, MSD, Tesaro, Lilly, Seagen, Gilead, GSK, Bayer, Amgen, Pierre Fabre, Roche; Financial Interests, Personal, Other, Travel Expenses: AstraZeneca, Pfizer. A.D. Hartkopf: Financial Interests, Personal, Other, Honoraria: AstraZeneca, GSK, MSD, Clovis, Miltenyi, Roche. I. Runnebaum: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, GSK, PharmaMar, Clovis, Roche, Tesaro; Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, PharmaMar, Fa. Martin, Tuttlingen, Fa. Caresyntax, Clovis, Tesaro, Roche; Financial Interests, Institutional, Coordinating PI: PharmaMar. P. Fasching: Financial Interests, Personal, Advisory Board: Roche, Novartis, Pfizer, Daiichi Sankyo, Eisai, Merck, Sharp & Dohme, AstraZeneca, Hexal, Lilly, Pierre Fabre, Seagen, Agendia, Sanofi Aventis; Financial Interests, Personal, Invited Speaker: Novartis, Daiichi Sankyo, Eisai, Merck, Sharp & Dohme, AstraZeneca, Lilly, Seagen, Gilead; Financial Interests, Personal, Other, Medical Writing Support: Roche; Financial Interests, Institutional, Local PI: BionTech, Cepheid; Non-Financial Interests, Member: ASCO, Arbeitsgemeinschaft für Gynäkologische Onkologie e.V., Translational Research in Oncology, Deutsche Gesellschaft für Senologie e.v. R. Glowik: Other, Personal, Sponsor/Funding, employee of AstraZeneca: AstraZeneca. J. Sehouli: Financial Interests, Institutional, Research Grant: GSK, Clovis, AstraZeneca, Roche, Bayer; Financial Interests, Personal, Speaker, Consultant, Advisor: MSD, AstraZeneca, Clovis, Roche, GSK, Tesaro, Novocure, PharmaMar, Eisai, Bayer, Merck. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.